Adjuvant therapy in pancreatic cancer

被引：32
|
作者：
Jones, Owain Peris [1 ]
Melling, James Daniel [1 ]
Ghaneh, Paula [1 ]
机构：
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L69 3GA, Merseyside, England
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2014年 / 20卷 / 40期
关键词：
Pancreatic cancer; Adjuvant; Gemcitabine; Chemotherapy; Chemoradiotherapy; Phase III; RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; CURATIVE RESECTION; RADIATION-THERAPY; FOLINIC ACID; REGIONAL HYPERTHERMIA; PERIAMPULLARY REGION; IMPROVED SURVIVAL; COOPERATIVE GROUP; PLUS GEMCITABINE;
D O I：
10.3748/wjg.v20.i40.14733
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase. trials in relation to adjuvant therapy in pancreatic cancer. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码：14733 / 14746
页数：14
相关论文
共 50 条
  • [31] Adjuvant Therapy of Pancreatic Cancer: Beyond Gemcitabine
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 106 - 109
  • [32] Adjuvant therapy for pancreatic cancer - The debate continues
    Choti, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12): : 1249 - 1251
  • [33] Development and controversies of adjuvant therapy for pancreatic cancer
    Lau, Wan-Yee
    Lai, Eric C. H.
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2008, 7 (02) : 121 - 125
  • [34] ADJUVANT AND SYSTEMIC THERAPY FOR PANCREATIC-CANCER
    CLARK, JW
    GLICKSMAN, A
    WANEBO, HJ
    SEMINARS IN SURGICAL ONCOLOGY, 1995, 11 (02): : 149 - 153
  • [35] Adjuvant therapy for pancreatic cancer: No 'Definite' standard
    Garofalo, Michael C.
    Abrams, Ross A.
    Regine, William F.
    ONCOLOGY-NEW YORK, 2007, 21 (06): : 726 - +
  • [36] FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer REPLY
    Malka, David
    Castan, Florence
    Conroy, Thierry
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1188 - 1189
  • [37] Adjuvant/Perioperative Therapy in Pancreatic and Periampullary Cancer
    Reilley, Matthew J.
    Shroff, Rachna
    Varadhachary, Gauri R.
    INDIAN JOURNAL OF SURGERY, 2015, 77 (05) : 403 - 408
  • [38] Adjuvant and neoadjuvant therapy for resectable pancreatic cancer
    Ueno, Hideki
    Okusaka, Takuji
    Kosuge, Tomoo
    Motoi, Fuyuhiko
    Unno, Michiaki
    ANNALS OF ONCOLOGY, 2015, 26 : 9 - 9
  • [39] Adjuvant therapy for pancreatic cancer: Back to the future
    Regine, WF
    Abrams, RA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01): : 59 - 63
  • [40] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25): : 2395 - 2406
12345